Stay updated on Intratumoral SD-101 + Pembrolizumab Clinical Trial
Sign up to get notified when there's something new on the Intratumoral SD-101 + Pembrolizumab Clinical Trial page.

Latest updates to the Intratumoral SD-101 + Pembrolizumab Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe footer revision label changed from v3.7.2 to v3.8.0, while the page continued to display a 403 error.SummaryDifference0.2%

- Check18 days agoChange DetectedA site-wide NIH banner announces transition updates and says federal agencies are using “Super Intelligence” in place of “Artificial Intelligence.”SummaryDifference1%

- Check25 days agoChange DetectedThe footer revision identifier changes from v3.7.1 to v3.7.2 while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check32 days agoChange DetectedThe footer’s site revision identifier changes from v3.7.0 to v3.7.1 on the 403 error page.SummaryDifference0.2%

- Check45 days agoChange DetectedThe study page is now blocked by a 403 error, showing only an error screen instead of the full study record and documents.SummaryDifference21%

- Check52 days agoChange DetectedRevision tag updated from v3.6.6 to v3.7.0 on the page, signaling an underlying update to the document version. This reflects an administrative or content-management update rather than a substantive change to study details.SummaryDifference0.0%

Stay in the know with updates to Intratumoral SD-101 + Pembrolizumab Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Intratumoral SD-101 + Pembrolizumab Clinical Trial page.